Kubota Y, Yanai H, Sasagawa I, Suzuki H, Nakada T, Sugano O
Department of Urology, Yamagata University School of Medicine, Japan.
Int Urol Nephrol. 1996;28(3):349-55. doi: 10.1007/BF02550497.
We assessed the relationship between changes in PSA and prognosis, as a possible reflection of tumour growth in patients who relapse following primary endocrine therapy. In 8 patients in whom no therapeutic change was attempted after PSA relapse, the PSA level increased exponentially. Their PSA-DT had a close positive relationship to the duration of survival after relapse (r = 0.79, p = 0.02). In 6 patients who received chemotherapy after relapse, PSA-DT between PSA relapse and initiation of chemotherapy also had a relationship to the duration of survival after relapse (r = 0.87, p = 0.05). It appears to be reasonable to conclude from these findings that the PSA-DT value is regarded to be a factor associated with prognosis in cases with an exponential increase in PSA after replase.
我们评估了前列腺特异性抗原（PSA）变化与预后之间的关系，以此作为初次内分泌治疗后复发患者肿瘤生长的一种可能反映。在8例PSA复发后未尝试进行治疗改变的患者中，PSA水平呈指数上升。他们的PSA倍增时间（PSA-DT）与复发后的生存时间密切正相关（r = 0.79，p = 0.02）。在6例复发后接受化疗的患者中，PSA复发至开始化疗之间的PSA-DT也与复发后的生存时间有关（r = 0.87，p = 0.05）。从这些发现似乎可以合理地得出结论，在复发后PSA呈指数上升的病例中，PSA-DT值被认为是与预后相关的一个因素。
